Prospect and progress of personalized peptide vaccinations for advanced cancers.
INTRODUCTION
The field of cancer immunotherapy has made dramatic progress in the past 20 years, in part due to the identification of numerous tumor-associated antigens (TAAs). We have developed a novel immunotherapeutic approach called the personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides are selected based on the pre-existing host immunity before vaccination.


AREAS COVERED
This review describes recent progress in the use of PPV for various types of advanced cancer.


EXPERT OPINION
Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the diverse and heterogeneous characteristics of tumor cells and host immunity seem to limit their therapeutic efficacy. Selection of suitable peptide vaccines for individual patients based on the pre-existing host immunity before vaccination could resolve this limitation and could be a rational approach for developing effective cancer vaccines.
['Sakamoto|Shinjiro|S|', 'Noguchi|Masanori|M|', 'Yamada|Akira|A|', 'Itoh|Kyogo|K|', 'Sasada|Tetsuro|T|']
D000818:Animals D000951:Antigens, Neoplasm D019496:Cancer Vaccines D006801:Humans D007167:Immunotherapy D009369:Neoplasms D010455:Peptides D057285:Precision Medicine D014611:Vaccination D022223:Vaccines, Subunit
personalized peptide vaccine Advanced cancer cancer immunotherapy cancer vaccine biomarker clinical trial peptide epitope